viewPreveCeutical Medical Inc.

PreveCeutical pleased with rodent model of opioid substitute pain-reliever

The company's lead peptides demonstrated pain relief activity for up to two hours at relatively low doses

scientists, one of whom is holding up what looks like a petri dish
It is also currently conducting pharmacokinetic studies, which analyze the movement of drugs within the body, on certain lead peptides

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H) announced Thursday that it has completed a successful rodent model of its opioid-replacement pain-relieving drug.

The model is part of an analgesic (read: pain relief) program the company launched in 2018 to develop peptide-based therapeutics for moderate-to-severe pain and inflammation. Peptides are made up of short chains of amino acids, which themselves are the building blocks of proteins.

In rodents, the peptides demonstrated analgesic activity at relatively low doses with effects lasting for up to two hours, the company said. Additionally, the peptides did not affect inflammation in the pain model, suggesting their effects were associated with an opioid-like analgesic effect.

READ: PreveCeutical hits milestone in opioid substitute pain-reliever

PreveCeutical is also currently conducting pharmacokinetic studies, which analyze the movement of drugs within the body, on certain lead peptides.

“We are looking forward to the results of the PK studies,” CEO Stephen Van Deventer said in a statement. “This brings us closer to finding non-addictive pain therapies. We will be investigating patenting the lead peptides once the study is completed. The company is looking forward to adding this to our pipeline of intellectual property."

PreveCeutical focuses on developing options for preventative and curative therapies utilizing organic and nature identical products. The company’s current R&D programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: PreveCeutical Medical Inc.

Price: 0.035 CAD

Market: CSE
Market Cap: $17.22 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...


PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 07/23/2020

2 min read